Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | GALR3 | O60755 | 1/20 | 0.55 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 13/20 | 0.53 |
| ▸ | AURKA | O14965 | 2/20 | 0.50 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
| ▸ | KRAS | P01116 | 1/20 | 0.47 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14713436 | 1.00 | LMNA (0.64) | LMNASMN1; SMN2HSD17B10GALR3NR2F2 | |
| SCHEMBL2623141 | 1.00 | LMNA (0.64) | LMNASMN1; SMN2HSD17B10GALR3NR2F2 | |
| SCHEMBL4569248 | 0.82 | LMNA (0.44) | LMNASMN1; SMN2HSD17B10GALR3NR2F2 | |
| SCHEMBL4572186 | 0.82 | RPS6KB1 (0.53) | LMNASMN1; SMN2HSD17B10EGFRAURKA | |
| SCHEMBL4569247 | 0.82 | LMNA (0.44) | LMNASMN1; SMN2HSD17B10GALR3NR2F2 | |
| SCHEMBL4572192 | 0.82 | RPS6KB1 (0.53) | LMNASMN1; SMN2HSD17B10EGFRAURKA | |
| SCHEMBL7773690 | 0.81 | LMNA (0.43) | LMNASMN1; SMN2HSD17B10GALR3NR2F2 | |
| SCHEMBL6016566 | 0.80 | LMNA (0.42) | LMNASMN1; SMN2HSD17B10EGFRAURKA | |
| SCHEMBL5019511 | 0.79 | MAP4K4 (0.40) | LMNASMN1; SMN2HSD17B10RAB9A | |
| SCHEMBL7778515 | 0.79 | LMNA (0.41) | LMNASMN1; SMN2HSD17B10GALR3NR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102812033-A | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof | INST MATERIA MEDICA CAMS | 2012-12-05 | — | — | CN | claimed |
| US-20220162215-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ INC (US) | 2022-05-26 | — | — | US | disclosed |
| WO-2020206363-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ,INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| EP-2427195-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-10174033-B2 | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2019-01-08 | — | — | US | disclosed |
| US-9388183-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9315505-B2 | Heterocyclic compounds and uses thereof | INTELLIKINE LLC (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150031672-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2015-01-29 | — | — | US | disclosed |
| US-8901133-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140296207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2014-10-02 | — | — | US | disclosed |
| US-8785454-B2 | Heterocyclic compounds and uses thereof | INTELLIKINE LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130045942-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2013-02-21 | — | — | US | disclosed |
| US-20130045942-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2013-02-21 | — | — | US | disclosed |
| CN-102812033-A | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof | INST MATERIA MEDICA CAMS | 2012-12-05 | — | — | CN | disclosed |
| WO-2012064973-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031672-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | LMNA 1475/4885SMN1; SMN2 1464/4885HSD17B10 1927/4885 |
| US-20220162215-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | NLN, PINK1, NME4 | LMNA 626/4885SMN1; SMN2 73/4885HSD17B10 903/4885 |
| US-10174033-B2 | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof | ADORA2A, ADORA3, ADORA1 | LMNA 812/4885SMN1; SMN2 330/4885HSD17B10 4656/4885 |
| US-20130045942-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | ADORA2A, ADORA3, ADORA1 | LMNA 812/4885SMN1; SMN2 330/4885HSD17B10 4656/4885 |
| US-20140296207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, AKT3, PIK3CD | LMNA 1113/4885SMN1; SMN2 2594/4885HSD17B10 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.